In this sense, it has been shown that erythropoietin (EPO), through the activation of its specific receptor, exerts neuroprotective effects by inhibiting proinflammatory processes and inhibiting the release of reactive oxygen species (oxidative stress) in re-induced models of Parkinsonism [10], Alzheimer’s disease [11], traumatic brain injury [12], cerebral ischemia [13], etc. Furthermore, EPO prevents neuronal death in the spinal cord in EAE models [14], and this molecule is produced in spinal cord cells such as astrocytes and neurons. Here, EPO is linked to early-onset autosomal dominant Alzheimer disease.